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Abstract
 
Human immunodeficiency virus (HIV)-1 infectivity requires actin-dependent clustering of
host lipid raft–associated receptors, a process that might be linked to Rho guanosine triphos-
phatase (GTPase) activation. Rho GTPase activity can be negatively regulated by statins, a family
of drugs used to treat hypercholesterolemia in man. Statins mediate inhibition of Rho GTPases
by impeding prenylation of small G proteins through blockade of 3-hydroxy-3-methylglutaryl
coenzyme A reductase. We show that statins decreased viral load and increased CD4
 
 
 
cell
counts in acute infection models and in chronically HIV-1–infected patients. Viral entry and
exit was reduced in statin-treated cells, and inhibition was blocked by the addition of 
 
l
 
-mevalonate
or of geranylgeranylpyrophosphate, but not by cholesterol. Cell treatment with a geranylgeranyl
transferase inhibitor, but not a farnesyl transferase inhibitor, specifically inhibited entry of HIV-1–
pseudotyped viruses. Statins blocked Rho-A activation induced by HIV-1 binding to target
cells, and expression of the dominant negative mutant RhoN19 inhibited HIV-1 envelope fusion
with target cell membranes, reducing cell infection rates. We suggest that statins have direct
anti–HIV-1 effects by targeting Rho.
Key words: cholesterol • actin cytoskeleton • small GTPases • lipid rafts • prenylation
 
Introduction
 
Despite the use of available prophylactic measures, HIV-1
infection constitutes a growing pandemic, particularly in
less developed countries, for which we lack adequate treat-
ment. The most common therapeutic regime, highly active
antiretroviral therapy (HAART), has improved the life
quality of many HIV-1–infected individuals. Nonetheless,
it is cumbersome, with serious side effects, and has resulted
in the emergence of drug-resistant viruses.
One area of HIV-1 research aims to understand the inter-
play between virus and host cell, to block key interactions
between virus and host target, and to prevent virus propa-
gation without the inconvenience of HAART. Effort has
concentrated on the HIV-1 entry and budding processes,
which require the formation of large clusters between viral
and host cell proteins (1). Results suggest that HIV-1 entry
into and exit from the host cell require actin cytoskeleton
rearrangement and adequate cholesterol levels in host and
viral membranes (2–13). A means remains to be found for
specific targeting of these host factors to prevent HIV-1
propagation with minimal toxicity.
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Statins are 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors used to treat hypercho-
lesterolemia. HMG-CoA reductase produces mevalonic
acid, a precursor for cholesterol biosynthesis and generation
of isoprenoids that modify specific cell proteins posttransla-
tionally. Rho guanosine triphosphatases (GTPases), which
must be prenylated at their C terminus for function, are
molecular switches that cycle between GTP-bound (active)
and GDP-bound (inactive) states to control actin cytoskel-
eton remodeling in response to stimuli (14). By targeting
HMG-CoA, statins block cholesterol biosynthesis, but also
affect actin cytoskeleton rearrangement by inhibiting Rho
GTPases (15).
We show that statins inhibited HIV-1 infection of SCID
mice grafted with adult human PBMCs (SCID-hu-PBMC),
an in vivo model of acute HIV-1 infection. Statins inhibited
virus entry into and exit from target cells by targeting Rho
geranylation. Strikingly, 1-mo oral statin administration
reduced serum HIV-1 RNA copy number in chronically
HIV-1–infected individuals not receiving HAART. Our
results indicate that statins might be suitable antiretroviral
drugs for more accessible AIDS treatment.
 
Materials and Methods
 
HIV-1 Infection.
 
Single-round infections were performed
with a replication-defective pNL4-3.Luc.R-E pseudotyped with
HIV-1
 
ADA 
 
or vesicular stomatitis virus (VSV)-G envelopes (2).
MT2-CCR5 cells (provided by J. Alcamí, Instituto de Salud Car-
los III, Madrid, Spain) were treated with 0.4, 2, or 10 
 

 
M lovastatin
(Lov) for 48 h at 37
 

 
C alone or with 200 
 

 
M 
 
l
 
-mevalonate
(Mev), 5 
 

 
M geranylgeranylpyrophosphate (GGPP), 5 
 

 
M far-
nesylpyrophosphate (FPP), or 5 
 

 
g/ml cholesterol (all from
Sigma-Aldrich), or with 10 
 

 
M GGTI-286 or 10 
 

 
M FTI-277
(both from Calbiochem) before transduction with viral superna-
tants (a multiplicity of infection of 0.1) for 2 h at 37
 

 
C. Infectivity
was determined after 24 h by measuring luciferase activity (2, 5).
Similar experiments were performed using MT2-CCR5 cells ex-
pressing GFP-tagged wild-type Rho, wild-type Rac, or the
Rho-N19 or Rac-N17 mutants (provided by F. Sánchez-
Madrid, Hospital de la Princesa, Madrid, Spain). gp160-induced
cell–cell fusion assays were as described previously (2).
PBMCs purified on Ficoll-Hypaque gradients (Amersham
Biosciences) were activated for 2 d with 1 
 

 
g/ml PHA and 50
ng/ml IL-2, and treated for 48 h at 37
 

 
C with Lov or Lov plus
Mev. Treated PBMCs were incubated with NL4-3 or BaL viral
stocks (1 or 10 ng p24 antigen/10
 
6 
 
cells) for 3 h at 37
 

 
C. Cell-free
supernatants were collected daily from cultured cells (0.5 
 
 
 
10
 
6
 
/
ml) and tested for p24 antigen (Beckman Coulter).
For ex vivo infection, PBMCs were purified from informed,
vehicle-, or pravastatin-treated donors (40 mg/d for 14 d, oral)
before and after treatment. PBMCs obtained before treatment
were frozen, and pre- and posttreatment cells were infected si-
multaneously with two infectious doses of HIV-1 BaL stocks. Af-
ter washing, cells (0.5 
 
 
 
10
 
6
 
 cells/ml) were plated with PHA and
IL-2, and cultured in the absence of statins. p24 was measured at
4 and 5 d after infection (Beckman Coulter).
 
Murine SCID-hu-PBMC Model.
 
8–10-wk-old nonleaky phe-
notype CB.17 SCID/SCID mice were reconstituted by i.p.
injection of 50 
 
 
 
10
 
6 
 
human PBMCs. 1 wk later, mice with
comparable serum human immunoglobulin levels, proof of re-
constitution with human cells, received 5 mg/kg Lov i.p. every
3 d, beginning 1 wk before HIV-1 NL4-3 i.p. challenge (100
TCID
 
50
 
/ml), until they were killed. Plasma HIV-1 RNA copy
number was measured (Amplicor HIV-1 Monitor Assay; Roche
Molecular Systems) 1 wk after infection. 2 wk after viral chal-
lenge, 10
 
6 
 
peritoneal cells from killed mice were incubated with
2 
 
 
 
10
 
6 
 
PHA-activated human PBMCs in the presence of IL-2,
and p24 was determined after 2 wk of coculture. Peritoneal cells
were also analyzed by FACS
 
® 
 
(EPICS Elite; Beckman Coulter)
using FITC-labeled anti-CD45 and PE anti-CD4 antibody (BD
Biosciences). Untreated or Lov-treated mice were reconstituted
with CellTracker Green CMFDA (Molecular Probes)-stained
PBMCs. At 3 and 7 d after reconstitution, peritoneal cells were
obtained from two mice, pooled, and analyzed by FACS
 
®
 
.
 
Titration of Viral Production.
 
HEK 293T cells, cotransfected
with pNL4-3.Luc.R.E. and cDNA encoding HIV-1
 
ADA 
 
or VSV-G
envelopes, were treated with Lov or Lov plus Mev. Viral stocks
were harvested after 48 h and titrated by measuring luciferase ac-
tivity after transduction of CD4-expressing HEK 293T cells. Val-
ues were normalized to luciferase activity from extracts of stock-
producing cells.
 
LTR-driven Gene Expression.
 
Jurkat cells transfected with
pLTR-luc (16), pcDNA-tat, and the promoterless renilla lu-
ciferase plasmid were treated at 4 h after transfection with inhibi-
tors and metabolites at the indicated concentrations (see HIV-1
Infection). Relative luciferase units were calculated as the ratio
between firefly and renilla activity after 48 h.
 
Cell Cholesterol Mass Determination.
 
Cholesterol content of
untreated, Lov-, or Lov plus Mev–treated MT2-CCR5 cells was
analyzed on a gas chromatograph (Chrompack; Hewlett-Packard)
as described previously (17). The cholesteryl ester mass was calcu-
lated by subtracting free cholesterol from total cholesterol content.
 
Rho and Rac Activation Assay.
 
3 
 
 
 
10
 
6 
 
starved MT2-CCR5
cells treated with Lov or Lov plus GGPP were incubated with
HIV-1 stocks. At the indicated times, cells were washed with ice-
cold PBS and lysates were prepared using Rho or Rac activation
assay kits (Upstate Biotechnology). GTP-bound Rho or Rac was
precipitated with RBD or PBD agarose beads, respectively, and
measured in pellets by Western blot with specific antibodies, us-
ing crude cell extracts for normalization. Densitometry was per-
formed using NIH Image software.
 
gp120-induced Patching.
 
Unstimulated PBMCs plated into
ICAM-2/Fc (R&D Systems)-coated chambers were incubated
for 30 min at 12
 

 
C with recombinant gp120 (T cell line–adapted
X4 virus, isolate IIIB; Intracel) in PBS/0.2% bovine serum albu-
min, followed by rabbit anti–gp120 and Cy2 anti–rabbit antibody
(Jackson ImmunoResearch Laboratories). Cells were fixed with
3.7% paraformaldehyde/PBS on ice, and then incubated sequen-
tially with biotinylated anti-CXCR4 (FAB172; R&D Systems)
and streptavidin-Cy3. Cells were mounted in Vectashield me-
dium (Vector Laboratories) and visualized by confocal micros-
copy (Leica).
 
Lov Effect on Ras Processing and Vesicle Fusion.
 
Lysates from
MT2-CCR5 cells treated with Lov, Lov plus cholesterol, Lov plus
FPP, GGTI, or FTI were resolved in 15% SDS-PAGE and blotted
with an anti–pan-Ras antibody (Oncogene Research Products).
For vesicle fusion assays, HEK 293 cells were incubated for 9
min at 37
 

 
C with 1 mg/ml biotinylated peroxidase (horseradish
peroxidase [HRP]) or 4 mg/ml avidin in Dulbecco’s PBS with 1
mM CaCl
 
2 
 
and 1 mM MgCl
 
2
 
. After washing, cells were homog-
enized in 3 mM imidazole/HCl, pH 7.4, and 250 mM sucrose by
several passages through a 23-gauge needle. Postnuclear superna-
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tants containing avidin or biotin HRP-loaded endosomes were
incubated for 1 h at 37
 

 
C in 10 mM Hepes-KOH, pH 7.0, 1.2
mM MgCl
 
2
 
, 50 mM KOAc, 0.8 mM DTT, biotin insulin (to
quench free avidin), and an ATP-regenerating system. Control
preincubations were performed in the absence of an ATP-regen-
erating system. Fusion was terminated by lysis with 0.25% Triton
X-100, and HRP activity in the complex was detected in avidin
immunoprecipitates.
 
Lov Treatment of HIV-1–infected Patients.
 
Six informed HIV-
1–infected patients in A1 disease stage who did not receive
HAART were treated with Lov (40 mg/d, oral) for 1 mo. Plasma
HIV RNA copy number, circulating CD4
 
 
 
T lymphocyte
counts, and plasma cholesterol levels were measured before and
immediately after treatment, as well as 3 mo after termination of
Lov treatment, using standard clinical techniques.
 
Online Supplemental Material.
 
gp120-induced patching and
the Lov effect on Ras processing and vesicle fusion are shown in
Figs. S1 and S2, respectively. Figs. S1 and S2 are available at http:
//www.jem.org/cgi/content/full/jem.20040061/DC1.
 
Results and Discussion
 
Statins Inhibit HIV-1 Infection In Vitro and In Vivo.
 
It is
suggested that statins have anti–HIV-1 effects (18). PHA-
activated human PBMCs, pretreated for 48 h with 10 
 

 
M
Lov, were exposed to X4 (NL4-3) or R5 (BaL) HIV-1
strains, and no cytotoxic effects were observed at this dosage
(not depicted). Lov inhibited HIV-1 infection, as indicated
by reduced p24 antigen production in X4- and R5-infected
cultures (Fig. 1 A). This effect was reversed by coincubation
of cells with 
 
l
 
-Mev, the product of HMG-CoA reductase.
To further assess the statin-induced anti–HIV-1 effect,
we compared susceptibility to R5 virus infection of PBMCs
from vehicle- or pravastatin-treated human volunteers iso-
lated before and after the treatment. PBMCs isolated before
and after vehicle treatment were equally infected by R5 vi-
ruses (Fig. 1 B; P 
 
 
 
0.812 for 1 ng of p24/10
 
6 
 
cells and P 
 

 
0.218 for 10 ng of p24/10
 
6 
 
cells, two-tailed Wilcoxon
Signed-Rank test). In contrast, PBMCs isolated from prava-
statin-treated volunteers were more resistant to HIV infec-
tion than PBMCs from the same individuals before treat-
ment (Fig. 1 B; P 
 
 
 
0.032 for both virus doses, two-tailed
Wilcoxon Signed-Rank test).
We tested whether statins blocked HIV-1 replication in
vivo in the SCID-hu-PBMC model (19) by injecting Lov
before HIV-1 NL4-3 challenge. Mean viral load was signif-
icantly reduced in Lov-treated mice (P 
 
 
 
0.028, two-tailed
Mann-Whitney test) compared with vehicle-treated ani-
mals (Fig. 1 C). Viral RNA was undetectable in plasma of 4
out of 10 Lov-treated mice, and coculture of peritoneal
cells from 2 of these mice with PHA-activated human
PBMCs did not rescue virus. At 1 wk after infection, Lov-
treated SCID-hu-PBMC mice showed higher CD4
 
 
 
T cell
counts than controls, and the average CD4
 

 
/CD45
 
 
 
ratio
was 51% in Lov- and 28% in vehicle-treated mice (Fig. 1
D), indicating specific CD4
 
 
 
cell loss in controls (P 
 

 
0.048, two-tailed Mann-Whitney test). In non-HIV–chal-
lenged controls, the CD4
 

 
/CD45
 
 
 
ratio was similar be-
tween untreated and Lov-treated mice. Lov affected nei-
ther CCR5 (69.7% untreated, 76.1% Lov treated) or
CXCR4 levels (56.5% untreated, 64.3% Lov treated). To
determine whether statins affected viability or proliferation
of grafted human cells, SCID mice were reconstituted with
fluorescent-labeled, PHA-activated human PBMCs and
Figure 1. Statins inhibit in vitro and in vivo
HIV-1 infection of human PBMCs. (A) Infection
of untreated (), Lov- (), or Lov plus Mev–
treated () PHA-activated human PBMCs by
X4 or R5 HIV-1 viral strains. Data are mean 
SD of triplicate points (n  3). (B) PBMCs iso-
lated from human volunteers, before and after
vehicle or pravastatin treatment, were exposed
to two doses of BaL HIV-1. Data are the ratio
between post- and pretreatment p24 levels for
PBMCs from each individual (**, P  0.05).
(C and D) Human PBMC-reconstituted SCID
mice were Lov treated for 1 wk before HIV-1
infection. Viral load (C) and human CD4/
CD45 ratio (D) was determined for each animal
1 wk after infection. One representative experi-
ment out of two is shown (**, P  0.05). The
CD4/CD45 ratio was also determined in non-
infected mice (D, right). (E) Lov-treated SCID
mice were reconstituted with CellTracker-stained
PBMCs and peritoneal cell labeling was exam-
ined at the indicated times. The numbers indi-
cate the percentage of labeled cells.
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were Lov treated as described above. As the label is distrib-
uted in each cell division, a deleterious Lov effect on
grafted PBMCs would produce a difference in label inten-
sity or in the number of labeled cells compared with un-
treated animals. We found no difference in the number of
labeled cells or in labeling intensity (Fig. 1 E).
 
Statins Affect the HIV-1 Replicative Cycle by Reducing Gera-
nylgeranylation.
 
We analyzed infection of untreated or
Lov-treated cells using the replication-defective HIV-1
NL4-3.Luc variant pseudotyped with HIV or VSV enve-
lopes. As the virus cannot replicate in the cell, luciferase ac-
tivity correlates with the ability of the virus to enter target
cells. Single-round infection experiments showed that Lov
inhibited entry of HIV-1 NL4-3.Luc pseudotyped with
HIV-R5 (Fig. 2 A) or X4 (not depicted) envelopes, but
not that of viruses pseudotyped with the VSV-G envelope.
The inhibitory effect of statin on HIV-1 entry was dose de-
pendent (Fig. 2 B). Lov treatment also reduced HIV-1-
X4–pseudotyped viral production, but not that of VSV-G–
pseudotyped viruses, by HEK 293T cells transfected with
replication-defective NL4-3.Luc DNA (Fig. 2 C). It is un-
likely that the specific Lov-induced reduction in HIV-1–
pseudotyped viral production is due to differential Gag syn-
thesis and processing because HIV-1 and VSV pseudotypes
share the same viral genome. Nonetheless, Lov increased
HIV-1 LTR-driven promoter activity (Fig. 2 D), as moni-
tored in cells transfected with a luciferase-encoding re-
porter under the control of HIV-LTR (pLTR-luc), sug-
gesting that the drug regulates the activity of nuclear factors
involved in HIV transcription. These results indicate that
Lov has both pro-HIV (increasing viral genome transcrip-
tion) and anti-HIV effects (inhibiting virus entry into and
virus production by the target cell). Both pro– and anti–
HIV-1 Lov-induced effects were mediated through the
Mev pathway, as they were reversed by coincubation of
cells with 
 
l
 
-Mev (Fig. 2, A, C, and D).
Inhibition of the Mev pathway diminishes cholesterol
biosynthesis, but also reduces cell pools of GGPP and FPP,
both of which are involved in posttranslational protein mod-
ification. We found that Lov-induced inhibition of HIV-1
entry into permissive cells was reversed by the coaddition of
GGPP, but not of FPP or cholesterol (Fig. 2 E). This sug-
gests that Lov inhibits HIV-1 infection by blocking protein
geranylgeranylation rather than by preventing farnesylation
or reducing cholesterol biosynthesis. R5-pseudotyped virus
entry was inhibited by cell treatment with a geranylgeranyl
transferase-I inhibitor (GGTI-286), but not a farnesyl trans-
ferase inhibitor (FTI-277; Fig. 2 F). These drugs did not af-
fect VSV-G–pseudotyped virus entry (not depicted). Mea-
surement of cell cholesterol content indicated comparable
free cholesterol levels in Lov-treated and untreated cells.
Nonetheless, the drug drastically reduced the cholesteryl es-
ter mass (Fig. 2 G), probably due to concomitant inhibition
of acyl-CoA:cholesterol acyltransferase (20). Although we
Figure 2. Statins inhibit HIV-1
entry and exit. (A) Single-round infec-
tions were performed in untreated,
Lov-, and Lov plus Mev–treated
MT2-CCR5 cells using a replication-
defective NL4-3 virus bearing the
luciferase reporter pseudotyped with
HIV-1Ada or VSV-G envelopes. Cell
infection was normalized using un-
treated cells as 100%. (B) MT2-
CCR5 cells were Lov treated (0.4,
2, or 10 M), and then exposed to
NL4-3 virus pseudotyped with
HIV-1Ada envelope. The x axis is in
log scale. (C) Virus production was
measured by titration of viral stocks
produced in untreated, Lov-, and
Lov plus Mev–treated HEK-293T
cells transfected with replication-
defective NL4-3 virus. Relative lu-
ciferase units were calculated after
normalization with luciferase activity
from extracts of stock-producing
cells. (D) LTR-driven gene expression
was analyzed in untreated, Lov-, or
Lov plus Mev–treated Jurkat cells
transfected with pLTR-Luc, pcDNA-
tat, and promoterless renilla for nor-
malization. (E) Single-round infec-
tion experiments were performed using replication-defective NL4-3 virus in MT2-CCR5 cells treated with Lov or Lov plus the indicated compounds.
Cell infection was normalized considering untreated cells as 100%. (F) Single-round infections performed with the HIV-1Ada–pseudotyped virus in MT2-
CCR5 cells treated with Lov, GGTI, or FTI. (G) Free or esterified cholesterol levels in untreated, Lov-, or Lov plus Mev–treated MT2-CCR5 cells.
One representative experiment out of two is shown. (H) LTR-driven gene expression in MT2-CCR5 cells treated with Lov, Lov plus the indicated
compounds, or with GGTI-286 or FTI-277. (A–E, G, and H) Data are mean  SD of duplicates (n  3). Significant differences are indicated: *, P 
0.05; **, P  0.01. Kruskal-Wallis test.
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cannot exclude a role for esterified cholesterol in HIV-1 in-
fection, the finding that GGPP reverses Lov-induced inhibi-
tion of virus entry suggests that Lov effects are mediated
mainly by impairment of protein geranylgeranylation. Sup-
plementation with GGPP, but not FPP or free cholesterol,
also reversed the Lov-induced increase in LTR-driven tran-
scription (Fig. 2 H). Cell treatment with a geranylgeranyl
transferase inhibitor also increased HIV transcription (Fig. 2
H), suggesting a general molecular mechanism for Lov me-
diation of pro– and anti–HIV-1 effects.
 
Statins Inhibit HIV-1 Infection by Down-regulating Rho Acti-
vation.
 
Geranylgeranylation is needed for posttranslational
lipid modification of several proteins anchored to the inner
membrane leaflet, including the Rho GTPases (15). More-
over, gp120 binding to target cells modifies Rho molecular
mass and increases Cdc42 expression (21). Target cell incu-
bation with HIV-1 resulted in activation of Rho, but not
Rac (Fig. 3 A) or Cdc42 (not depicted). Cell incubation
with Lov before virus exposure inhibited HIV-1–induced
Rho activation, which was reversed when cells were coin-
cubated with GGPP (Fig. 3, B and C), indicating that Lov
prevented HIV-1–induced Rho activation by a geranylger-
anylation-dependent mechanism. Virus-induced Rho acti-
vation is required for virus entry because infection by R5-
pseudotyped HIV-1 was reduced in dominant negative
RhoN19 mutant-expressing cells (Fig. 3 D). RhoN19 ex-
pression also specifically prevented HIV-1 envelope fusion
with target cell membrane in a cell–cell fusion assay (Fig. 3
E). The results suggest that Lov inhibits HIV-1 entry into
target cells, at least in part, by preventing Rho activation.
Rho inhibition has been associated with an increase in
HIV-1 transcription (22), suggesting that Lov-induced
pro– and anti–HIV-1 effects might be Rho mediated.
 
Statins Reduce Plasma HIV RNA Copy Number in Chroni-
cally Infected Individuals.
 
Statins are used for treatment of
HAART-associated lipodystrophy. Based on our in vitro
results, we tested the potential use of statins for in vivo
treatment of HIV patients. In a preliminary study for proof
of concept, six A1 stage HIV-1–infected, non-HAART–
treated patients with stable viral load for at least 6 mo were
Lov treated for 1 mo as sole therapy. Short-term statin
treatment induced a clear reduction in serum viral RNA
loads in all patients (Table I). Discontinuation of statin
treatment caused a rebound in viral load (Table I). The data
suggest that statins can inhibit HIV-1 replication in chroni-
cally infected individuals, and support future clinical studies
of statins as possible antiretroviral agents.
Statins may have several immune cell targets (23, 24).
We show that statin-induced inhibition of HIV-1 entry
and virion production, as well as the increase in viral tran-
scription, is mediated via Mev pathway inhibition. HIV-1
entry and budding are cooperative processes that require
protein coaggregation at the host cell surface: CD4 and the
chemokine coreceptors for entry, and Gag and gp160 for
budding (1). It is suggested that these processes are medi-
ated by protein association with lipid rafts (2–5, 25–27) and
driven by the actin cytoskeleton (11–13). Raft clustering
entails actin cytoskeleton reorganization, for which Rho
might be a key effector (28). Statins can inhibit HIV-1 in-
fection in part by reducing Rho prenylation, essential for
Rho localization and function, including the cytoskeletal
reorganization required for virus entry and exit. Indeed,
although Lov did not affect gp120 binding to CD4, colo-
calization between gp120 and CXCR4 was drastically
reduced in Lov-treated cultures. Mev addition restored
gp120-CXCR4 colocalization in Lov-treated cells (Fig. S1,
available at http://www.jem.org/cgi/content/full/jem.
20040061/DC1). Nonetheless, statins are general inhibitors
of protein prenylation. We found that Lov treatment
inhibited Ras farnesylation and 
 

 
25% vesicle fusion, a
process mediated by prenylated Rab GTPases (Fig. S2,
available at http://www.jem.org/cgi/content/full/jem.
Figure 3. Statins inhibit HIV-1 infection by down-regulating Rho ac-
tivation. (A) Serum-starved MT2-CCR5 cells were incubated with HIV-
1 and cell lysates were assayed for active Rho or Rac. Total Rho or Rac
was analyzed in parallel in crude cell extracts as a protein loading control.
One experiment out of three is shown. Black line indicates that different
sections of the same gel were juxtaposed. (B) Active Rho was determined
in untreated, Lov-, or Lov plus GGPP–treated cells, as described above.
Total Rho in crude cell extracts is shown as a loading control. One repre-
sentative experiment out of three is shown. (C) Western blots from three
independent experiments as in B were quantified by densitometry and
values were normalized using Rho in crude cell extracts as a loading con-
trol. Data points are plotted relative to mean values of cells not exposed to
virus (time 0) for each condition. (D) Single-round infections of MT2-
CCR5 cells transfected with mock, wild-type Rho, or mutant Rho-N19
using an HIV-1Ada–pseudotyped, replication-defective virus. *, P  0.05.
Kruskal-Wallis test. (E) HeLa-CD4 cells transfected with wild-type Rac,
wild-type Rho, Rac-N17, or Rho-N19 were mixed with HIV gp160–
expressing BSC40 cells. Cell fusion events were measured and normalized
relative to mock transfected cells. *, P  0.05. Kruskal-Wallis test. (D and
E) Data are mean  SD of duplicate points (n  3).
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20040061/DC1). Although our results establish a role for
Rho in HIV-1 entry, we cannot exclude the involvement
of other prenylated proteins.
In summary, we provide evidence that statins prevent
HIV-1 infection in cultured primary cells, in animal mod-
els, and in chronically infected individuals. We show that at
the cellular level, statins inhibit viral entry and budding by
preventing Rho geranylgeranylation. Based on the ability
of statins to lower viral load in HIV-1–infected individuals,
we suggest that these compounds have direct antiretroviral
effects and might be appropriate drugs for more accessible
treatment of the AIDS pandemic.
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